Everything Coming up Rosy is not a Health Tune
People with the chronic inflammatory skin condition rosacea shouldn’t skip out on check-ups. According to a new research study from…
07/18/2024
Everything Coming up Rosy is not a Health Tune
People with the chronic inflammatory skin condition rosacea shouldn’t skip out on check-ups. According to a new research study from…
|
07/02/2024
Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
By Mandi Murph Treatment may be changing for patients with Stage III melanoma. Recent clinical trial results show improved outcomes…
|
07/02/2024
In Plain English: Overview of the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO)
By Kim Margolin, M.D., FACP, FASCO The American Society of Clinical Oncology or ASCO is a professional organization that…
|
|
06/06/2024
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in…
|
|
04/11/2024
Interview with Allison Betof Warner, MD, PhD: TIL Therapy
The following is an edited and shortened version of our recent interview with Allison Betof Warner, MD, PhD about the…
|
04/11/2024
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma
By Kim Margolin, M.D., FACP, FASCO Note: We are rerunning an update on this TIL therapy article that originally ran…
|
|
03/15/2024
The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
|
|
02/17/2024
Iovance Biotherapeutics Announces Approval for TIL Therapy
The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
|
|
01/18/2024
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool The DermaSensor device demonstrates a high rate of sensitivity in the detection…
|
|
10/23/2023
Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
|
|
Recent Posts
Jul. 23, 2024
From a Scare to Awareness: Lindsay Willis’s Mission to Educate on Melanoma Risks
Jul. 18, 2024
Everything Coming up Rosy is not a Health Tune
Jul. 10, 2024
Ways to Give: How You Can Donate Your Birthday Through Facebook
Jul. 10, 2024
Beyond the Clinic Podcast: Navigating the Storm: Managing Stress and Anxiety Through Your Cancer Journey
Jul. 02, 2024